These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 3134542)

  • 1. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
    Gresele P; Blockmans D; Deckmyn H; Vermylen J
    J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
    Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
    J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor.
    Bertelé V; Falanga A; Tomasiak M; Cerletti C; de Gaetano G
    Thromb Haemost; 1984 Feb; 51(1):125-8. PubMed ID: 6326343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrathoracic platelet accumulation in the guinea-pig induced by intravenous administration of arachidonic acid--effect of cyclooxygenase and thromboxane synthetase inhibitors.
    Barrett PA; Butler KD; Shand RA; Wallis RB
    Thromb Haemost; 1986 Dec; 56(3):311-7. PubMed ID: 3105107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetyl glycerylphosphorylcholine aggregates human platelets through two distinct pathways, both dependent on arachidonic acid metabolism.
    Macconi D; Morzenti G; Livio M; Morelli C; Cassina G; Remuzzi G
    Lab Invest; 1985 Feb; 52(2):159-68. PubMed ID: 3155816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 2-indolecarbohydrazides on thromboxane synthetase activity and on in vitro and ex vivo blood platelet aggregation. New selective inhibitors.
    Monge A; Erro A; Parrado P; Font M; Aldana I; Rocha E; Fernandez-Alvarez E
    Arzneimittelforschung; 1986 Aug; 36(8):1184-6. PubMed ID: 3096343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2.
    Gresele P; Deckmyn H; Huybrechts E; Vermylen J
    Biochem Pharmacol; 1984 Jul; 33(13):2083-8. PubMed ID: 6430299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B; Arnout J; Deckmyn H; Vermylen J
    Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
    Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
    Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation.
    Seiler S; Brassard CL; Arnold AJ; Meanwell NA; Fleming JS; Keely SL
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1021-6. PubMed ID: 2175792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products.
    Bertelé V; Falanga A; Tomasiak M; Chiabrando C; Cerletti C; de Gaetano G
    Blood; 1984 Jun; 63(6):1460-6. PubMed ID: 6426554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet reactivity in vitro in relation to thromboxane in healthy pregnancy.
    Horn EH; Hardy E; Cooper J; Heptinstall S; Rubin PC
    Thromb Haemost; 1996 Feb; 75(2):346-51. PubMed ID: 8815588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat.
    Ashida SI; Abiko Y
    Thromb Haemost; 1979 Apr; 41(2):436-49. PubMed ID: 224522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
    Zahavi M; Zahavi J; Kakkar VV
    Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets.
    Gresele P; Deckmyn H; Arnout J; Nenci GG; Vermylen J
    Thromb Haemost; 1989 Jun; 61(3):479-84. PubMed ID: 2552606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
    Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
    Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mepacrine blockade of arachidonate-induced washed platelet aggregation: relationship to mepacrine inhibition of platelet cyclooxygenase.
    Raz A
    Thromb Haemost; 1983 Dec; 50(4):784-6. PubMed ID: 6420923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lag-phase of arachidonic acid-induced secretion in responders and non-responders to the thromboxane-synthetase inhibitors: involvement of cyclic-AMP.
    Lecompte T; Joussemet M; Hainaut J
    Thromb Res; 1984 Jul; 35(1):91-7. PubMed ID: 6089368
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.